The Discount Reached the Boardroom
The FDA paused Biohaven's pivotal epilepsy enrollment fifteen days after its up to $795M SK deal, an Artisan Partners manager demanded Novartis board changes, Axogen paid $200M for sutureless nerve repair, and the surrogate discount week closed with nothing round tripped.
